Extracellular vesicles (EVs) have emerged as key players in intercellular communication, carrying a diverse range of biomolecules. Recent research on EV glycosylation has shed light on its pivotal role in cancer. This review aims to provide a comprehensive overview of the significance of EV glycosylation in cancer, covering specialized techniques for isolating and characterizing EV glycosylation, how glycosylation influences biogenesis and uptake of EVs, and its involvement in various cellular processes and potential applications in immunotherapy. By delving into recent advances in EV glycosylation research within the context of different cancers such as lung, colorectal, liver, pancreatic, breast, ovarian, prostate, and melanoma, this review aims to equip researchers with valuable insights to explore new avenues in cancer diagnostics and therapeutics.
EVs, categorized into exosomes, microvesicles, and apoptotic bodies, play essential roles in both physiological and pathological processes, with their cargoes reflecting cellular events and states. Glycosylation, a common post-translational modification, significantly impacts the properties and functions of proteins present on EVs. Tumor-derived EVs are enriched with tumor-associated glycans, influencing their biosynthesis and function, thus serving as potential sources of diagnostic biomarkers. Various glycosylation types such as N-glycosylation and O-glycosylation play significant roles in modulating physiological processes, including cancer cell behaviors like proliferation, metastasis, and immune evasion.
Isolating and characterizing EVs and their glycosylation content is crucial for in-depth analysis. Techniques such as ultracentrifugation, size exclusion chromatography, and affinity-based methods are commonly employed for EV isolation. Enrichment methods like size exclusion chromatography and lectin-based affinity enrichment facilitate the purification of EVs for subsequent glycosylation analysis. Analytical methods such as mass spectrometry, Western blotting, and lectin assays are used to elucidate glycosylation patterns, providing valuable insights into the biogenesis and uptake of EVs.
Glycosylation influences the biogenesis and uptake of EVs, impacting various biological processes. Studies have shown that distinct glycosylation patterns on EVs can affect their biogenesis pathways and interactions with recipient cells. Glycosylation also plays a crucial role in modulating the expression of proteins associated with EVs, influencing processes like metastasis and immune responses. Understanding the glycosylation profiles of EVs is essential for deciphering their roles in intercellular communication and disease progression.
In the context of cancer, investigating the glycosylation of EVs holds promise for early diagnosis, prognosis assessment, and therapeutic development. Studies have revealed distinct glycomic profiles in EVs derived from different cancer types, suggesting the potential of EV glycosylation as diagnostic and prognostic biomarkers. Glycosylation of EVs in cancers like lung, colorectal, liver, pancreatic, breast, ovarian, prostate, and melanoma presents opportunities for innovative diagnostic and therapeutic strategies, addressing the urgent need for effective cancer management in the global population.
Tags: affinity chromatography, transduction, downstream, analytical methods, chromatography, immunotherapy, biomarkers, centrifugation, size exclusion, cell culture
Read more on pmc.ncbi.nlm.nih.gov